Effectiveness, safety, and biomarker dynamics of lecanemab in Chinese Alzheimer's disease population: a multicenter real-world study - PubMed
7 hours ago
- #Alzheimer's disease
- #Real-world study
- #Lecanemab
- Lecanemab, an anti-amyloid beta (Aβ) protofibril antibody, was studied in a real-world Chinese Alzheimer's disease population.
- The study involved 261 patients across 21 sites, with cognitive tests, plasma biomarkers, and optional PET scans over 6 months.
- Results showed significant attenuation of cognitive decline compared to the ADNI cohort, with robust changes in plasma biomarkers like Aβ42, Aβ40, p‑tau217, and GFAP.
- A reduction in p‑tau217 correlated with amyloid PET clearance, with 29.2% of patients turning amyloid-negative.
- APOE ε4 non-carriers showed greater improvements, suggesting a genetic influence on treatment response.
- Safety profile included infusion reactions in 11.1% and amyloid-related imaging abnormalities in 9.2%, with only 1.6% symptomatic.
- The study concluded that lecanemab is effective and well-tolerated in real-world Chinese patients, with plasma p‑tau217 as a potential biomarker for treatment response.